Real-world safety of first-line enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: evidence from VigiBase and FAERS
BackgroundCompared with platinum-based chemotherapy, the combination of enfortumab vedotin and pembrolizumab (EV + Pembro) achieves higher durable response rates and improves survival outcomes in patients with locally advanced or metastatic urothelial carcinoma. As the first regimen pairing an immun...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Frontiers Media S.A.
2026-06-01
|
| Reeks: | Frontiers in Immunology |
| Onderwerpen: | |
| Online toegang: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1759135/full |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|